Cellular Immunotherapy Program

The mission of the Mass General Cellular Immunotherapy Program is to invent, develop, administer, and understand engineered immune effector cells.

Support us

Explore the Cellular Immunotherapy Program

Overview

The mission of the Mass General Cellular Immunotherapy Program is to invent, develop, administer, and understand engineered immune effector cells. Our approach is to expand cellular engineering and immunotherapy research by bringing together physicians and laboratory scientists focused on immune cell engineering and its clinical effects. We aim to enhance the cohesion between biological, translational, and clinical aspects of cell engineering to implement safe and potent immunotherapies, with the ultimate goal of developing curative treatments for cancer and other diseases.

Our objectives:

We aim to enhance the cohesion between biological, translational, and clinical aspects of cell engineering to implement safe and potent immunotherapies.

Bring together clinical researchers who administer, manage, and/or investigate immune effector cells as a therapeutic modality
Enable translational research and collaboration
Optimize immune monitoring and laboratory correlatives of clinical observations
Promote cellular therapy education through education sessions
Provide high quality care and management of patients receiving cellular therapies
Obtain and maintain FACT accreditation for the administration of immune effector cells
Invent and develop novel forms of cellular engineering that will become the next generation of immune cell therapies

Clinical Trials

View Cellular Therapy clinical trials.

CAR T-Cell Therapies

Mass General Cancer Center is an authorized treatment center for FDA approved CAR T-cell therapies for adult patients with lymphoma (Breyanzi, Kymriah, Tecartus and Yescarta) and for adult patients with multiple myeloma (Abecma). Learn more.

Meet the Team

Lead by Marcela Maus, MD, PhD, the Cellular Immunotherapy Program brings together physicians and laboratory scientists focused on immune cell engineering and its clinical effects.

Meet the Cellular Immunotherapy team

Marcela Maus, MD, PhD
- Director, Cellular Immunotherapy Program
- Associate Professor of Medicine, Harvard Medical School

Videos

Noopur Raje, MD, Marcela Maus, MD, PhD and Matthew Frigault, MD discuss the power and evolution of immune therapies, specifically, CAR T-Cell therapy in treating cancer.

Of the many different approaches to activate the body’s immune system against cancer, CAR T-cell therapy is one of the most high tech and powerful treatments.

Marcela V. Maus, MD, PhD, Director of the Cellular Immunotherapy Program at the Mass General Cancer Center, was awarded a 2017 Stand Up to Cancer Innovative Research Grant for her work on "Potentiating Novel Engineered Cellular Therapies for Solid Tumors."

Kiss 108 FM’s Billy Costa talks with four experts from the Mass General Cancer Center to learn about what CAR T-cell therapy is and what impact it has on both patients and the medical community.

Kiss 108 FM’s Billy Costa gets a doctor’s perspective of CAR T-cell therapy with Mass General Cancer Center’s clinical director for the Center of Lymphoma, Dr. Jeremy Abramson.

Kiss 108 FM’s Billy Costa sits down with Dr. Marcela Maus, director of cellular immunotherapy at the Mass General Cancer Center, and discusses what CAR T-cell therapy is, who is eligible for treatments, and the future direction of CAR T-cell therapy.

Kiss 108 FM’s Billy Costa discusses CAR T-cell therapy with Mass General Cancer Center’s Dr. Matthew Frigault, medical oncologist and administrative director for Cellular Therapy Services, who explains how this therapy has the potential to impact patients in immense ways.

Watch how Mass General patient Jenn Gilmann has already benefited from immunotherapy.

1 of 8

Clinical Trials

View Cellular Therapy clinical trials.

CAR T-Cell Therapies

View CAR T-Cell Therapies.

Publications

View publications by Marcela Maus, MD, PhD on PubMed.

FACT Standards

FACT Standards for Immune Effector Cells.

FACT information

The why, what, and how of the new FACT standards for immune effector cells.

Maus Lab

Learn about the Maus laboratory.

Immune Monitoring Lab

Learn about the Immune Monitoring laboratory.

Cellular Therapy & Transplantation Lab

Learn about the Cellular Therapy & Transplantation Laboratory.

Blood Transfusion Service

Learn about Mass General's Blood Transfusion Service.

Honors & Awards

View Cellular Immunotherapy Program team members honored for their commitment to the fight against cancer.

Marcela V. Maus, MD, PhD

As the director of the Cellular Immunotherapy Program at the Mass General Cancer Center, Marcela Maus, MD, PhD, is following a childhood dream of fixing genes gone wrong in the pursuit of a cure for cancer.

Featured Articles

Contact the Cancer Center

Contact the Mass General Cancer Center to make an appointment or learn more about our programs.

Request an appointment Clinical trials and research 617-726-5130

The Mass General Difference

Conditions & Treatments

Patients & Visitors

Research & Innovation

Mass General
Cancer Center

Cellular Immunotherapy Program